Results 71 to 80 of about 4,153 (212)

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

ESC Heart Failure
Aims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce.
Gonzalo Luis Alonso Salinas, Amaia Martínez León, Diego Aguiar Cano, Alberto Esteban‐Fernández, José María Viéitez Flórez, Susana delPrado Díaz, Juan Górriz‐Magaña, Gregorio deLara Delgado, Rafael González‐Manzanares, Pedro Caravaca‐Pérez, Francisco J. Pastor‐Pérez, Sandra Valdivieso‐Moré, Juan Quiles, Inés Ponz, Vanessa Escolar, Edison Omar Boada Lincango, Néstor Báez‐Ferrer, Gonzalo Gallego, Luis Almenar, Luis Gutiérrez de la Varga, Pau Codina, Alejandro Recio Mayoral, Aleix Fort, María Jesús Pinilla Lozano, David González‐Calle, Inés Gómez‐Otero, Cristina Salazar Mosteiro, Marta Cobo, Jesús Piqueras‐Flores, Clara Bonanad, Ana Huerta, Maria Ferré Vallverdú, Pablo Díez‐Villanueva   +32 more
doaj   +1 more source

Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction:A FINE-HEART Analysis [PDF]

Background: Pooling data from participants with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) from all completed outcomes trials evaluating finerenone to date may enhance ...
Agarwal, Rajiv, Amarante, Flaviana, Anker, Stefan D., Brinker, Meike, Claggett, Brian L., D. Henderson, Alasdair, Desai, Akshay S., Filippatos, Gerasimos, Jhund, Pardeep S., Lam, Carolyn S.P., Lay-Flurrie, James, McMurray, John J.V., Miao, Zi Michael, Ostrominski, John W., Pitt, Bertram, Rohwedder, Katja, Rossing, Peter, Ruilope, Luis M., Scheerer, Markus F., Senni, Michele, Shah, Sanjiv J., Solomon, Scott D., Vaduganathan, Muthiah, Voors, Adriaan A., Zannad, Faiez   +24 more
core   +1 more source

Mechanisms of hesperetin in alleviating diabetic nephropathy: Network pharmacology, molecular docking, and experimental validation

Journal of Diabetes Investigation, Volume 17, Issue 4, Page 576-587, April 2026.
Hesperetin increases cell viability and reduces cell apoptosis, ferroptosis, release of inflammatory cytokines, and oxidative stress of human kidney tubular cells via repressing IGF1R expression. ABSTRACT Background Diabetic nephropathy (DN) accounts for approximately 50% of chronic kidney disease cases.
Yiwen Guo, Fengjiao Zhang, Yu Jin, Menglu Zhu, Zhiqiang Kang   +4 more
wiley   +1 more source

Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials. [PDF]

BACKGROUND: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a novel therapeutic option for the management of patients with diabetes, chronic kidney disease, or heart failure. We seek to summarize the evidence on the drugs
Ahmed, Mushood, Ahmed, Raheel, Ahsan, Areeba, Fonarow, Gregg, Fudim, Marat, Iqbal, Javed, Jain, Hritvik, Maniya, Muhammad, Naveed, Muhammad, Rana, Jamal, Shafiq, Aimen   +10 more
core   +1 more source

GLP‐1 Receptor Agonists for the Prevention of New‐Onset Heart Failure: A Systematic Review and Meta‐Analysis of Placebo‐Controlled Randomized Clinical Trials

Obesity Reviews, Volume 27, Issue 4, April 2026.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) improve outcomes in heart failure (HF) with preserved ejection fraction. Whether GLP‐1 RA prevent new‐onset HF in Type 2 diabetes or obesity requires further investigation. Methods We performed an updated meta‐analysis of randomized placebo‐controlled trials (RCT) of treatment ...
João Sérgio Neves, Carolina B. Lobato, Ana Rita Leite, Catarina Vale, Francisco Vasques‐Nóvoa, Francisca Saraiva, Adelino Leite‐Moreira, Jens J. Holst, João Pedro Ferreira   +8 more
wiley   +1 more source

Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials

BMJ Open
Objectives This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex.Design FIDELITY post hoc analysis; median follow-up ...
George L Bakris, Peter Rossing, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Shweta Bansal, Maria E F Canziani, Rita Birne, Luis M Ruilope, Alfredo E Farjat, Peter Kolkhof, Andrea Lage, Meike Brinker   +12 more
doaj   +1 more source

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

Cardiovascular Diabetology, 2023
Background In the Netherlands, more than one million patients have type 2 diabetes (T2D), and approximately 36% of these patients have chronic kidney disease (CKD).
Sara W. Quist, Alexander V. van Schoonhoven, Stephan J. L. Bakker, Michał Pochopień, Maarten J. Postma, Jeanni M. T. van Loon, Jeroen H. J. Paulissen   +6 more
doaj   +1 more source

A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial [PDF]

Publisher Copyright: Copyright © 2024 Chimura M et al.Importance: Sex is associated with the clinical presentation, outcomes, and response to treatment in patients with heart failure (HF).
Chimura, Misato, Claggett, Brian L., Desai, Akshay S., Fonseca, Cândida, Glasauer, Andrea, Goncalvesova, Eva, Henderson, Alasdair D., Jhund, Pardeep S., Katova, Tzvetana, Lam, Carolyn S.P., McMurray, John J.V., Mueller, Katharina, Nodari, Savina, Pitt, Bertram, Rohwedder, Katja, Saldarriaga, Clara Inés, Senni, Michele, Sharma, Kavita, Solomon, Scott D., Vaduganathan, Muthiah, Vardeny, Orly, Viswanathan, Prabhakar, Voors, Adriaan A., Wang, Xiaowen, Zannad, Faiez   +24 more
core   +1 more source

Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin–Angiotensin System Inhibitors Therapy

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT We evaluated the renal outcomes and safety of spironolactone added to renin–angiotensin system inhibitors (RASis) among patients with type 2 diabetes (T2D), given its uncertain role alongside RASis, the cornerstone of T2D with renal disease management.
Wei‐Ren Lin, Tzu‐Shan Huang, Ho‐Hsiang Chang, Jo‐Yen Chao, Yi‐Hsin Chang, Chen‐Yi Yang, Huang‐Tz Ou, Wei‐Hung Lin   +7 more
wiley   +1 more source

Progression of albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) over 24 years in people with type 2 diabetes. Drivers, potential protectors and associated mortality

Diabetic Medicine, Volume 43, Issue 3, March 2026.
Abstract Introduction The pathophysiology of chronic kidney disease (CKD) and type 2 diabetes (T2D) is multifactorial and associated with a plethora of underlying conditions and complications. Their link is reciprocal and understanding its nature, particularly over time, could improve the health of many.
Andreas Matheou, Orestis Zavlis, Steve White, Thomas McDonnell, Alexander Warner‐Levy, John Warner‐Levy, Loren Wilkins, Hellena Habte‐Asres, Abigail Lay, Liliana Shalamanova, Martin Whyte, Martin Gibson, Philip A. Kalra, Adrian Heald   +13 more
wiley   +1 more source